The multi-award-winning LED phototherapy company specialises in the development of innovative energy-based devices for the medical, aesthetic and cosmetic markets. Omni acquired Dermalux (formerly known as Aesthetic Technology Ltd.), the UK market leader in LED phototherapy, in early 2023.
Chris Spooner joins Dermalux with over 30 years of experience as a seasoned aesthetics industry executive, with nearly 20 of those years spent as an accomplished CEO. In his last role, Chris was the CEO at Sinclair Pharma. Under his leadership, Sinclair Pharma expanded from a small medical dermatology company to a global aesthetics player focused on innovative brands and technologies. Chris successfully transformed the business from a loss-making enterprise into a highly profitable aesthetics-focused healthcare company, multiplying revenue tenfold.
Since Omni’s investment in Dermalux, the brand has launched two new products, with several others currently in the development pipeline nearing launch. At the same time, Omni has worked with Dermalux on a major rebrand, ensuring product positioning reflects the premium best-in-market Dermalux product line. Chris’ prior experience expanding Sinclair Pharma’s commercial geographic footprint will be instrumental in delivering Dermalux’s vision of growing their market share internationally, building upon recent expansion into 24 countries.
Charles Gallagher-Powell, Partner at Omni, said:
“We are excited to work with Chris as we help Dermalux accelerate its growth on the back of the initiatives currently underway. Chris’ successful track record at Sinclair aligns fully with the strategic direction we aspire to pursue at Dermalux. We believe that he can replicate that same success at Dermalux.”
Chris Spooner, CEO at Dermalux, said:
“I am thrilled to join Dermalux at a time when the aesthetics industry has become a global growth phenomenon by offering ever improving and more medically beneficial outcomes. I look forward to growing the Dermalux brand into a global leader in medical LEDs and more broadly into other anti-ageing device technologies and aesthetics consumables.”
Omni is focused on investing in fast-growing companies seeking their first external capital, providing capital and expertise to turbocharge their growth.
